Paul Bisaro - Zoetis Independent Director

ZTS -- USA Stock  

Fiscal Quarter End: December 31, 2019  

  Director
Mr. Paul M. Bisaro is Independent Director of the Company. Mr. Bisaro was the Executive Chairman of the board of directors of Allergan plc from July 2014 to October 2016. Until June 2014, Mr. Bisaro formerly served as President and Chief Executive Officer from March 2017 to May 2018. Mr. Bisaro was the Executive Chairman of the board of directors of Allergan plc from July 2014 to October 2016. Until June 2014, Mr. Bisaro served as Board Chairman, President and Chief Executive Officer of Actavis, a global pharmaceutical company . He was appointed President, Chief Executive Officer and a member of the board of Watson Pharmaceuticals in September 2007 and was later appointed Chairman of the board of Watson Pharmaceuticals in October 2013. Prior to joining Watson, Mr. Bisaro was President, Chief Operating Officer and a member of the board of Barr Pharmaceuticals, Inc., a global specialty pharmaceutical company, from 1999 to 2007. Between 1992 and 1999, Mr. Bisaro served as General Counsel of Barr, and from 1997 to 1999 served in various additional capacities including Senior Vice President Strategic Business Development. Prior to joining Barr, Mr. Bisaro was associated with the law firm Winston Strawn and a predecessor firm, Bishop, Cook, Purcell and Reynolds from 1989 to 1992. Mr. Bisaro currently serves on the Board of Visitors of The Catholic University of Americas Columbus School of Law. Mr. Bisaro previously served on the boards of Allergan plc from 2007 to 2018 and Zimmer Biomet Holdings, Inc., a world leader in musculoskeletal health solutions, from 2013 to 2017. Mr. Bisaro holds an undergraduate degree in General Studies from the University of Michigan and a Juris Doctor from The Catholic University of America in Washington, D.C. Mr. Bisaros business, management and leadership experience, his understanding of the pharmaceutical industry, and his public company board experience make him a valuable member of our Board.
Age: 57  Director Since 2015      
973 822-7000  www.zoetis.com
Bisaro holds an undergraduate degree in General Studies from the University of Michigan and a Juris Doctor from The Catholic University of America in Washington, D.C.

Paul Bisaro Latest Insider Activity

Management Efficiency

The company has Return on Asset of 11.71 % which means that on every $100 spent on asset it made $11.71 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 60.93 % implying that it generated $60.93 on every 100 dollars invested.
The company has 6.66 B in debt with debt to equity (D/E) ratio of 248.5 . This implies that the company may be unable to create cash to meet all of its financial commitments. Zoetis has Current Ratio of 4.3 demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Herman MorrisPerrigo Company Plc
1999
Theodore SamuelsPerrigo Company Plc
2017
Rolf ClassonPerrigo Company Plc
2017
Leo PuriDr Reddys Laboratories Ltd
2018
Anupam PuriDr Reddys Laboratories Ltd
2002
George SingRegeneron Pharmaceuticals
1988
Larry CordellOrigin Agritech Limited
2012
Ashok GangulyDr Reddys Laboratories Ltd
2009
Lloyd CarneyVertex Pharmaceuticals Incorpor
2019
Terrence KearneyVertex Pharmaceuticals Incorpor
2011
Shikha SharmaDr Reddys Laboratories Ltd
2019
Joseph GoldsteinRegeneron Pharmaceuticals
1991
William YoungVertex Pharmaceuticals Incorpor
2014
Bonnie BasslerRegeneron Pharmaceuticals
2016
Margaret McGlynnVertex Pharmaceuticals Incorpor
2011
Huda ZoghbiRegeneron Pharmaceuticals
2016
Anthony ColesRegeneron Pharmaceuticals
2017
Min TangOrigin Agritech Limited
2009
Prasad MenonDr Reddys Laboratories Ltd
2019
Geoffrey ParkerPerrigo Company Plc
2016
Bradley AlfordPerrigo Company Plc
2017

Entity Summary

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. The company was founded in 1952 and is headquartered in Parsippany, New Jersey. Zoetis operates under Drug ManufacturersSpecialty Generic classification in USA and is traded on BATS Exchange. It employs 10000 people.Zoetis (ZTS) is traded on BATS Exchange in USA and employs 10,000 people.

Zoetis Leadership Team

Roman Trawicki, Executive Vice President and Presidentident of Global Manufacturing and Supply
Kristin Peck, Executive Vice President and Group President, U.S. Operations, Business Development and Strategy
William Steere, Independent Director
Roxanne Lagano, Executive Vice President, Chief Human Resources Officer and Communications
Linda Rhodes, Independent Director
Frank DAmelio, Independent Director
Robert Scully, Independent Director
Clinton Lewis, Executive Vice President and Group President, International Operations, Commercial Development, Global Genetics, Aquatic Health and Human Medical Diagnostics
Stefan Weiskopf, Executive Vice President and Area President of the Asia Pacific, Australia and New Zealand
Sanjay Khosla, Independent Director
Paul Herendeen, CFO and Executive VP
Catherine Knupp, Executive Vice President, President - Research and Development
Michael McCallister, Non-Executive Independent Chairman of the Board
Paul Bisaro, Independent Director
Alejandro Bernal, Executive Vice President and Area President of the Europe, Africa and Middle East region
Willie Reed, Independent Director
Joyce Lee, Executive Vice President and Area President of the Canada and Latin America region
Glenn David, Chief Financial Officer, Executive Vice President
Sandra Beaty, Executive Vice President - Corporate Affairs
William Doyle, Director
Andrew Fenton, Executive Vice President and Chief Digital and Technology Officer
Gregory Norden, Independent Director
Louise Parent, Independent Director
Heidi Chen, Executive Vice President General Counsel, Corporate Secretary
Juan Alaix, Chief Executive Officer, Director

Stock Performance Indicators

Did you try this?

Run Idea Breakdown Now

   

Idea Breakdown

Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
All  Next Launch Module

Also Currentnly Active

Purchased few shares of
few hours ago
Traded for 11.44
Purchased few shares of
few hours ago
Traded for 24.64
Purchased few shares of
few hours ago
Traded for 28.16
See also Your Current Watchlist. Please also try Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Search macroaxis.com